Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




RFA Eases Symptoms of Inoperable Lung Cancer

By HospiMedica staff writers
Posted on 22 Nov 2004
A pair of studies has shown that radiofrequency ablation (RFA), guided by computed tomography (CT), is effective in easing the symptoms of inoperable lung cancer, while changes in the size of the tumor as shown on CT determines whether that ablation was successful.

Researchers from S. More...
Sebastiano Hospital (Caserta, Italy) analyzed 33 patients with malignant lung cancer who could not undergo surgery and opted for CT-guided RFA instead. No major complications occurred and all sessions were deemed successful at follow-up CT.

The study was prompted by the feeling that an alternative to the usual therapies for lung cancer was strongly needed. "We see too many lung cancer patients who, inoperable for a number of different reasons, are left with few chances to obtain an effective palliation,” noted lead author Guiseppe Belfiore, M.D. "For sure, RFA allows a better quality of life for many inoperable patients.”

In the second study, researchers from National University Hospital (Chonbuk, South Korea) determined that pattern enhancement--a difference in contrast between a tumor and the surrounding tissue--and changes in tumor size were the most important factors in judging the success of RFA for lung tumors on CT. They analyzed 21 patients who had undergone CT-guided RF, nine who had complete ablations and 12 who had partial ablations. For the former group, the researchers found tumors were without any enhancement on short-term follow-up CT and that the size of the lesions had decreased by 40% after 12 months. For the partially ablated group, the tumors were enhanced to various degrees short-term and the tumor size had increased after six months.

The studies were published in the October 2004 issue of the American Journal of Roentgenology.




Related Links:
Chonbuk National University Hospital

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Surgical Headlight
IsoTorch
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.